Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis-Reference-Cited by-同舟云学术

Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis

Published:2019-02-15 Issue:2 Volume:185 Page:297-310
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Socié Gérard¹^ORCID,Caby‐Tosi Marie‐Pierre²,Marantz Jing L.³,Cole Alexander⁴,Bedrosian Camille L.⁵,Gasteyger Christoph⁶,Mujeebuddin Arshad⁴,Hillmen Peter⁷,Vande Walle Johan⁸,Haller Hermann⁹

Affiliation:

1. Hematology/Transplantation APHP Hospital Saint Louis University Paris VII Paris France

2. Alexion Europe SAS Rueil‐Malmaison France

3. Alexion Pharmaceuticals, Inc. Lexington MAUSA

4. Alexion Pharmaceuticals, Inc. BostonMAUSA

5. Alexion Pharmaceuticals, Inc. New Haven CT USA

6. Alexion Pharma GmbH Zürich Switzerland

7. St James's University Hospital Leeds UK

8. University Hospital Ghent Ghent Belgium

9. Hannover Medical School Hannover Germany

Funder

Alexion Pharmaceuticals

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.15790

Reference71 articles.

1. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)

2. Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab

3. Eculizumab for Atypical Hemolytic Uremic Syndrome in Pregnancy

4. Epidemiology of haemolytic uremic syndrome in children. Data from the North Italian HUS network

5. History of Meningococcal Outbreaks in the United States: Implications for Vaccination and Disease Prevention

Cited by 165 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complement system activation: bridging physiology, pathophysiology, and therapy;Intensive Care Medicine;2024-09-10

2. The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms;Drug Discovery Today;2024-09

3. Reproductive Health in Kidney Transplant Recipients;Advances in Kidney Disease and Health;2024-09

4. Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab;Kidney International Reports;2024-09

5. Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors;International Journal of Molecular Sciences;2024-08-31